Pfizer-birthed Ziarco raises $33m for skin drugs
This article was originally published in Scrip
A company formed by Pfizer's former head of allergy and respiratory research in Sandwich, UK, has raised $33.1m in a series B round to fund development of novel candidates to treat atopic dermatitis and psoriasis. Ziarco, headed by Mike Yeadon, will use the funds to complete proof of concept Phase II trials of its two lead candidates.
You may also be interested in...
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.